Viewpoint: Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business.
作者信息
Aisen P S, Raman R
机构信息
R. Raman, Director of Biostatistics, Alzheimer's Therapeutic Research Institute (ATRI), Director, Biostatistics Unit, Alzheimer's Clinical Trials Consortium (ACTC), Keck School of Medicine of USC, University of Southern California, 9860 Mesa Rim Road, San Diego, CA 92121, USA, Phone: 858-964-0673,
出版信息
J Prev Alzheimers Dis. 2020;7(3):195-196. doi: 10.14283/jpad.2020.20.
PMID:32463073
Abstract
摘要
相似文献
1
Viewpoint: Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business.
J Prev Alzheimers Dis. 2020;7(3):195-196. doi: 10.14283/jpad.2020.20.
2
The Future of Anti-Amyloid Trials.
J Prev Alzheimers Dis. 2020;7(3):146-151. doi: 10.14283/jpad.2020.24.
3
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
Expert Rev Clin Immunol. 2012 Feb;8(2):135-49. doi: 10.1586/eci.11.93.
4
Antibody drugs for Alzheimer's show glimmers of promise.
Nature. 2015 Jul 30;523(7562):509-10. doi: 10.1038/nature.2015.18031.
5
Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
JAMA. 2021 May 4;325(17):1717-1718. doi: 10.1001/jama.2021.3854.
6
Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
Indian J Pharmacol. 2016 Nov-Dec;48(6):629-636. doi: 10.4103/0253-7613.194867.
7
Alzheimer antibody drugs show questionable potential.
Nat Rev Drug Discov. 2015 Sep;14(9):591-2. doi: 10.1038/nrd4709.
8
[Immunotherapy for Alzheimer's disease].
Ugeskr Laeger. 2016 Jan 18;178(3):V07150588.
9
Landmark Alzheimer's drug approval confounds research community.
Nature. 2021 Jun;594(7863):309-310. doi: 10.1038/d41586-021-01546-2.
10
Commentary: The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux.
J Prev Alzheimers Dis. 2020;7(3):199-200. doi: 10.14283/jpad.2020.29.
引用本文的文献
1
Decision making in clinical trials: Interim analyses, innovative design, and biomarkers.
Alzheimers Dement (N Y). 2023 Oct 18;9(4):e12421. doi: 10.1002/trc2.12421. eCollection 2023 Oct-Dec.
2
Challenges in Implementing Futility Schemes, with Reference to Aducanumab.
Ther Innov Regul Sci. 2023 May;57(3):515-520. doi: 10.1007/s43441-023-00499-0. Epub 2023 Feb 3.
3
Putting participants and study partners FIRST when clinical trials end early.
Alzheimers Dement. 2022 Dec;18(12):2736-2746. doi: 10.1002/alz.12732. Epub 2022 Aug 2.
4
Early termination of pivotal trials in Alzheimer's disease-Preserving optimal value for participants and science.
Alzheimers Dement. 2022 Oct;18(10):1980-1987. doi: 10.1002/alz.12605. Epub 2022 Feb 27.
Zotero 插件